Lord, Abbett & Co
NGM

Lord, Abbett & Co’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Lord, Abbett & Co’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-132,426
Closed -$1.73M – 658
2022
Q3 		$1.73M Hold
132,426
– – 0.01% 541
2022
Q2 		$1.7M Sell
132,426
-800
-0.6% -$11.1K 0.01% 543
2022
Q1 		$2.03M Sell
133,226
-52,375
-28% -$817K 0.01% 586
2021
Q4 		$3.29M Buy
185,601
+200
+0.1% +$3.84K 0.01% 576
2021
Q3 		$3.9M Sell
185,401
-3,700
-2% -$81.5K 0.01% 606
2021
Q2 		$3.73M Buy
+189,101
New +$4.43M 0.01% 617

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's NGM Position: Q4 2022 in Review

Lord, Abbett & Co sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 132,426 shares — an estimated $1.73M sold.

Lord, Abbett & Co first reported a position in NGM in Q2 2021 and held it in 6 quarters. The position peaked at $3.9M in Q3 2021. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

  • Lord, Abbett & Co reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 132,426 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $1.73M.
  • Lord, Abbett & Co first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
  • Lord, Abbett & Co's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $3.9M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Lord, Abbett & Co's 13F filing for Q4 2022, filed 10 Feb 2023.